Evidence map›Paper›PMID 27028298›Full record

ArticlePloS one2016

Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake.

Masroor Shariff, Maryka Quik, Joan Holgate, Michael Morgan, Omkar L Patkar, Vincent Tam, Arnauld Belmer, Selena E Bartlett

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. About Sugar Addiction.Brain and behavior · 2025
    Review
  3. Article
  4. Article
  5. The potential effect of α7 nicotinic receptors modulation on palatable food-induced dependence-like behaviors.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Masroor ShariffInstitute of Health and Biomedical Innovation, Queensland University of Technology at Translational Research Institute, Brisbane, Australia.
Maryka QuikCentre for Health Sciences, Bioscience Division, SRI International, Menlo Park, California, United States of America.
Joan HolgateInstitute of Health and Biomedical Innovation, Queensland University of Technology at Translational Research Institute, Brisbane, Australia.
Michael MorganInstitute of Health and Biomedical Innovation, Queensland University of Technology at Translational Research Institute, Brisbane, Australia.
Omkar L PatkarInstitute of Health and Biomedical Innovation, Queensland University of Technology at Translational Research Institute, Brisbane, Australia.
Vincent TamSchool of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia.
Arnauld BelmerInstitute of Health and Biomedical Innovation, Queensland University of Technology at Translational Research Institute, Brisbane, Australia.
Selena E BartlettInstitute of Health and Biomedical Innovation, Queensland University of Technology at Translational Research Institute, Brisbane, Australia.
Queensland University of Technology · AUSRI International · USTranslational Research Institute · AU

Funding

Mechanisms of nicotine-mediated decrease in L-dopa induced-dyskinesiasR01NS059910 · NINDS · SRI INTERNATIONAL · PI QUIK, MARYKA · 2009 to 2013
$3.7M
NINDS NIH HHS NS59910NINDS NIH HHS R01 NS059910
6 · The paper itself

Abstract

Excess sugar consumption has been shown to contribute directly to weight gain, thus contributing to the growing worldwide obesity epidemic. Interestingly, increased sugar consumption has been shown to repeatedly elevate dopamine levels in the nucleus accumbens (NAc), in the mesolimbic reward pathway of the brain similar to many drugs of abuse. We report that varenicline, an FDA-approved nicotinic acetylcholine receptor (nAChR) partial agonist that modulates dopamine in the mesolimbic reward pathway of the brain, significantly reduces sucrose consumption, especially in a long-term consumption paradigm. Similar results were observed with other nAChR drugs, namely mecamylamine and cytisine. Furthermore, we show that long-term sucrose consumption increases α4β2 * and decreases α6β2* nAChRs in the nucleus accumbens, a key brain region associated with reward. Taken together, our results suggest that nAChR drugs such as varenicline may represent a novel treatment strategy for reducing sugar consumption.

Indexed as

AlkaloidsAnimalsAzocinesDrug Evaluation, PreclinicalFood PreferencesMaleMecamylamineNicotinic AgonistsNicotinic AntagonistsNucleus AccumbensQuinolizidine AlkaloidsQuinolizinesRats, WistarReceptors, NicotinicSucroseVareniclineAlkaloidsAzocinescytisineMecamylamineNicotinic AgonistsNicotinic AntagonistsQuinolizidine AlkaloidsQuinolizinesReceptors, NicotinicSucroseVarenicline

Identifiers

PMID27028298
PMCPMC4814119
OpenAlexW2315882511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.